News

Filter

Current filters:

RocheResearch

1 to 9 of 174 results

Targeted lung cancer therapies supplanting conventional drugs; report

03-03-2015

Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in…

AstraZenecaBristol-Myers SquibbEli LillyMarkets & MarketingMerck & ConecitumumabOncologyOpdivoPharmaceuticalResearchRoche

Pfenex soars on Lucentis biosimilar deal with Hospira

Pfenex soars on Lucentis biosimilar deal with Hospira

10-02-2015

Shares of US clinical-stage biotech firm Pfenex leapt 28% to $8.85 in morning trading, after the company…

BiosimilarsBiotechnologyGenentechGlobalHospiraLicensingLucentisNovartisOphthalmicsPF582PfenexResearchRoche

Roche announces positive Phase III results of Gazyva in non-Hodgkin's lymphoma

Roche announces positive Phase III results of Gazyva in non-Hodgkin's lymphoma

04-02-2015

Swiss drug major Roche has announced positive results from the Phase III study of Gazyva (obintuzumab)…

GazyvaOncologyPharmaceuticalResearchRoche

Chugai to expand Singapore R&D unit with $476 million investment

03-02-2015

Japan's Chugai Pharmaceutical, which is majority owned by Swiss pharma giant Roche, plans to invest $476…

Chugai PharmaceuticalFinancialPharmaceuticalResearchRocheSingapore

Roche, Meiji and Fedora team up to commercialize antibiotic OP0595

Roche, Meiji and Fedora team up to commercialize antibiotic OP0595

13-01-2015

Swiss pharma major Roche, Japanese pharma company Meiji Seika and private biotech company Fedora have…

Antibiotics and Infectious diseasesMeiji Seika PharmaOP0595PharmaceuticalResearchRoche

23andMe and Genentech in deal to analyze genomic data for Parkinson's disease

06-01-2015

23andMe, the leading personal genetics company, and Genentech, a subsidiary of Swiss pharma giant Roche,…

23andMeBiotechnologyGenentechNeurologicalResearchRoche

Roche ends Phase III trial of gantenerumab in prodromal Alzheimer’s disease

Roche ends Phase III trial of gantenerumab in prodromal Alzheimer’s disease

22-12-2014

Swiss drug major Roche is to end the Phase III study of experimental anti-amyloid drug gantenerumab in…

gantenerumabNeurologicalPharmaceuticalResearchRocheSwitzerland

1 to 9 of 174 results

COMPANY SPOTLIGHT

Menarini

Back to top